মন্টিনিগ্রো - ক্রোয়েশীয় - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo sa ograniČenom odgovornoŠĆu "inpharm co" podgorica - daratumumab - koncentrat za rastvor za infuziju - 20mg/ml

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - multipli mijelom - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. u kombinaciji s бортезомибом, талидомидом i дексаметазоном za liječenje odraslih bolesnika s prvi put utvrđenom multiplog mijeloma, koji imaju pravo za obavljanje autologna transplantacija matičnih stanica . u kombinaciji s леналидомидом i дексаметазоном i бортезомибом i дексаметазоном za liječenje odraslih bolesnika s multiplog mijeloma, koji je dobio barem jedne prethodne terapije. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. u monoterapiji za liječenje odraslih bolesnika s ponavljajućom i uporan multiplog mijeloma, čija je ranije terapija je uključivala inhibitor протеасом i иммуномодулирующего agent i koji je pokazao napredovanje bolesti na zadnje terapije. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

janssen-cilag international nv - Устекинумаб - psoriasis; arthritis, psoriatic; crohn disease; colitis, ulcerative - imunosupresivi - diseasestelara kruna je indiciran za liječenje odraslih bolesnika s bolešću reumatoidnim kruna, koji su imali neadekvatan odgovor, izgubila odgovor, ili iz netrpeljivosti ili tradicionalne terapije ili antagonist tnf ili imaju medicinske kontraindikacije za takvu terapiju. colitisstelara ulcerozni indiciran za liječenje odraslih bolesnika s вмеру na strogo aktivno язвенному колиту, koji su imali neadekvatan odgovor, izgubila odgovor, ili iz netrpeljivosti ili tradicionalne terapije ili biološke ili medicinske kontraindikacije za takvu terapiju. peglanje psoriasisstelara propisan za liječenje srednje teške i teške forme бляшечного psorijaze kod odraslih, koji nije mogao odgovoriti, ili koji imaju kontraindikacije ili netoleranciju druge sistemske terapije, uključujući ciklosporin, metotreksat i псоралена uv. vrtić plak psoriasisstelara propisan za liječenje srednje teške i teške forme бляшечного psorijaze u djece i adolescenata oboljelih u dobi od 6 i više godina, koji adekvatno prati, ili ne podnose, druge sistemske terapije, ili phototherapies. psorijatični arthritisstelara, odvojeno ili u kombinaciji sa metotreksatom prikazana za liječenje aktivnog psorijatični artritis kod odraslih pacijenata, kada je u odgovor na prethodne brojeve-biološka bolest-mijenjanje противоревматические lijekovi (dmards) terapija je bila neadekvatna..

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psorijaza - imunosupresivi - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - Геморрагическая groznice ebole - cjepiva - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - Геморрагическая groznice ebole - cjepiva - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multipli mijelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multipli mijelom - antineoplastična sredstva - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multipli mijelom - antineoplastična sredstva - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.